• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Infect Dis . SARS-CoV-2 Vaccination boosts Neutralizing Activity against Seasonal Human Coronaviruses

tetano

Editor, Senior Moderator
Clin Infect Dis


. 2022 Jan 25;ciac057.
doi: 10.1093/cid/ciac057. Online ahead of print.
SARS-CoV-2 Vaccination boosts Neutralizing Activity against Seasonal Human Coronaviruses


Jan Lawrenz[SUP] 1 [/SUP], Qinya Xie[SUP] 1 [/SUP], Fabian Zech[SUP] 1 [/SUP], Tatjana Weil[SUP] 1 [/SUP], Alina Seidel[SUP] 1 [/SUP], Daniela Krnavek[SUP] 1 [/SUP], Lia van der Hoek[SUP] 2 [/SUP], Jan Münch[SUP] 1 [/SUP], Janis A Müller[SUP] 1 [/SUP], Frank Kirchhoff[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Most of the millions of people that are vaccinated against SARS-CoV-2, the causative agent of COVID-19, have previously been infected by related circulating human coronaviruses (hCoVs) causing common colds and will experience further encounters with these viruses in the future. Whether or not COVID-19 vaccinations impact neutralization of seasonal coronaviruses is largely unknown.
Methods: We analyzed the capacity of sera derived from 24 individuals before and after heterologous ChAdOx1 nCoV-19 BNT162b2 prime-boost vaccination to neutralize genuine OC43, NL63 and 229E hCoVs, as well as viral pseudoparticles carrying the SARS-CoV-1, SARS-CoV-2, MERS-CoV, hCoV-OC43, -NL63 and -229E spike proteins. Genuine hCoVs or spike containing pseudovirions were incubated with different concentrations of sera and neutralization efficiencies were determined by measuring viral RNA yields, intracellular viral nucleocapsid expression, or reporter gene expression in Huh-7 cells.
Results: All individuals showed strong preexisting immunity against hCoV-OC43. Neutralization of hCoV-NL63 was more variable and all sera showed only modest inhibitory activity against genuine hCoV-229E. SARS-CoV-2 vaccination resulted in efficient cross-neutralization of SARS-CoV-1 but not of MERS-CoV. On average, vaccination significantly increased the neutralizing activity against genuine hCoV-OC43, -NL63 and -229E.
Conclusions: Heterologous COVID-19 vaccination may confer some cross-protection against endemic seasonal coronaviruses.

Keywords: COVID-19 vaccination; cross-neutralization; seasonal coronaviruses.
 
Back
Top Bottom